CTRI/2020/12/030118尚未招募3 期
International, open-label, randomized, comparative efficacy and safety study of Indacaterol, inhalation capsules 150 µg (LLC PSK Pharma, Russia) and Onbrez® Breezhaler®, inhalation capsules 150 µg (Novartis Pharma AG, Switzerland) in patients with COPD
PSK Pharma LLC0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.The presence of a signed Informed Consent Form of Patient Information Sheet (PIS) for participation in a clinical study.
- •2.Male and female patients aged 40â??70 years old inclusive at the time of signing the Informed Consent Form of PIS.
- •3.A diagnosis of moderate-grade COPD, established according to the GOLD guidelines, 2018, at least 12 months before the screening visit.
- •4.Patients corresponding to group B, according to GOLD, 2018
排除标准
- •1.Patients requiring initial treatment for COPD.
- •2.Hypersensitivity to indacaterol or any of the components of the drug.
- •3.Lactose intolerance, lactase deficiency or glucose-galactose malabsorption.
- •4.Demand for excessive use of SABAs
研究者
相似试验
暂停
不适用
efficacy and safety of Ciclesonide, metered-dose inhalerCTRI/2020/09/027824PSK Pharma LLC
已完成
不适用
To compare effectiveness and drug safety of Flusal, aerosol for inhalation metered dose and Seretide®, inhalation aerosol metered dose in patients with uncontrolled and partially controlled bronchial asthmaCTRI/2015/11/006380OOO Rus Biopharm120
进行中（未招募）
1 期
_EUCTR2014-002560-33-FRICANCER180
进行中（未招募）
1 期
_EUCTR2014-002560-33-BEICANCER180
进行中（未招募）
1 期
PALbociclib rechallenge in hormone receptor-posItive/HER2-negative advanced breast cancer (PALMIRA)Hormone receptor-positive/HER2-negative Advanced Breast CancerMedDRA version: 21.1Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 100000004864EUCTR2017-002781-48-DEMedica Scientia Innovation Research (MedSIR)198